Epizyme (EPZM) Skyrockets on Milestone Payments and Numbers

Epizyme, Inc. (EPZM)

Shares of EPZM soared on Tuesday's trading session after the company reported the achievement of the proof of concept (POC) milestone in the EPZ-5676 DOT1L inhibitor clinical program, earning a $25 million payment under the company's collaboration with Celgene Corporation.

The milestone was triggered by objective responses in patients with translocations of the MLL gene (MLL-r). These patients are currently enrolled in the fourth dose cohort in the dose escalation stage of the ongoing Phase 1 clinical study and are receiving uninterrupted treatment with EPZ-5676.

EPZM also said that a development candidate milestone has been achieved for one of the three histone methyltransferase (HMT) targets included in the company's collaboration with GlaxoSmithKline (GSK), earning a $4 million payment .

Additionally, the European Medicines Agency's Committee for Orphan Medicinal Products recommended orphan drug designation for EPZ-5676 to the European Commission in December 2013. EPZ-5676 was granted orphan drug designation by the U.S. Food and Drug Administration in May 2013

Including the Celgene POC milestone and the GSK development candidate milestone, EPZM estimates a 2013 end-of-year cash and account receivables position of approximately $145 million versus previous guidance of an end-of-year cash position of more than $115 million.

EPZM is developing EPZ-5676, a small molecule inhibitor of DOT1L created with the company's proprietary product platform, for the treatment of patients with acute leukemia in which the MLL gene is rearranged due to a chromosomal translocation (MLL-r) or a partial tandem duplication (MLL-PTD). Due to these rearrangements, DOT1L is misregulated, resulting in the increased expression of genes causing leukemia.

EPZM believes that EPZ-5676 was the first HMTi to enter human clinical development.

EPZM is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers.

More about Epizyme, Inc. (EPZM) at www.epizyme.com

**

Crown Equity Holdings Inc. (CRWE)

Social networking is a way for people to connect and share information with each other online. Millions of people worldwide regularly access these types of services from mobile devices, applications, and websites. According to statistics published by some of the most well-known social networking services, there are more than 500 million active users on Facebook, 175 million registered users on Twitter, more than 100 million users on MySpace, and more than 80 million members on LinkedIn

A social networking service is an online service, platform, or site that focuses on facilitating the building of social networks or social relations among people who, for example, share interests, activities, backgrounds, or real-life connections.

CRWE is looking to deliver value for its stockholders in both the near and long term, and to improve the potential future growth for the company, is targeting the multi-billion dollar social networking service market.

CRWE is currently developing a social networking service and phone app, CRWE Network ( CRWE-PR.com ), that is designed to target all the communities in every state of the United States, with its geographic focus starting in Southern California and Las Vegas Nevada.

CRWE ‘s business plan is based on selling advertising to local businesses. Its goal is to facilitate exchanges of goods and services in a manner similar to Craigslist, a classified advertisements website with sections devoted to jobs, housing, personals, for sale, items wanted, services, community, gigs, résumés, and discussion forums.

CRWE offers advertising branding and marketing services as a worldwide online multi-media publisher.

More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com .

**

Read Full Disclaimer at www.drstockpick.com/disclaimer